News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Roche and KSQ Therapeutics Reach Global License Agreement for KSQ-4279, an Advanced USP1 Inhibitor for Cancer Therapy
Friday, July 14, 2023The molecule is currently in Phase clinical trials for solid tumors and has shown promising potential based on preclinical data Under the agreement Roche will take over the development of KSQ allowing KSQ to focus on advancing its immunotherapy prog...
Kamada and Kedrion Agree to Extend U.S. Distribution Agreement for KEDRAB® by Two Years
Thursday, July 13, 2023Kamada Ltd NASDAQ KMDA TASE KMDATA announced today that Kedrion has exercised its option to extend the distribution agreement with Kamada in the United States for KEDRAB Rabies Immune Globulin Human
George Medicines Concludes Recruitment for Initial Phase III Trial Assessing Innovative Single-pill Triple Combination Candidate GMRx2 in Hypertension
Thursday, July 13, 2023George Medicines a company specializing in latestage drug development and focused on revolutionizing the management of cardiometabolic disease has announced the successful completion of patient enrollment in its Phase III activecontrolled trial
Enterome Initiates Phase 2 Trial for EO2040 Immunotherapy in Colorectal Cancer, Focusing on Minimal Residual Disease Identified by ctDNA
Wednesday, July 12, 2023Enterome a clinicalstage company has initiated a Phase clinical trial called CLAUDE at The University of Texas MD Anderson Cancer Center to evaluate their novel immunotherapy candidate EO in patients with colorectal cancer CRC
Initiation of First Patient Dosing in Phase 1/2 Clinical Trial Investigating SAR'514/IPH6401 for Relapsed/Refractory Multiple Myeloma
Wednesday, July 12, 2023Innate Pharma SA Euronext Paris IPH Nasdaq IPHA has made an announcement regarding the initiation of a Phase clinical trial sponsored by Sanofi NCT This trial aims to assess the safety pharmacokinetics and preliminary efficacy of SAR IPH in patient...
QurAlis Granted Clinical Trial Authorization (CTA) in the U.K. for QRL-201: A First-of-its-Kind Precision Therapy for ALS Targeting STATHMIN-2
Wednesday, July 12, 2023QurAlis Corporation recently announced that the Medicines and Healthcare Products Regulatory Agency MHRA in the United Kingdom has accepted their Clinical Trial Application CTA for QRL a potential treatment for amyotrophic lateral sclerosis ALS
Tango Therapeutics Commences TNG462 Phase 1/2 Trial, Administering Initial Dose to Patients Affected by MTAP-deleted Solid Tumors
Tuesday, July 11, 2023Tango Therapeutics Inc NASDAQ TNGX has recently initiated a phase clinical trial for their drug candidate TNG targeting patients with MTAPdeleted solid tumors TNG is a PRMT inhibitor that works in conjunction with MTA and has received Fast Track des...
Acasti Partners With Wuxi Clinical as CRO for STRIVE-ON Pivotal Phase 3 Safety Trial of GTX-104 in aSAH Patients
Tuesday, July 11, 2023Acasti Pharma Inc Nasdaq ACST has announced its partnership with WuXi Clinical Development Inc a subsidiary of WuXi AppTec to conduct the Phase safety trial for GTX an injectable nimodipine formulation developed by Acasti
FDA Grants Rare Pediatric Disease Designation to Myopax for Breakthrough Regenerative Cell Product in Exstrophy-epispadias Complex
Tuesday, July 11, 2023MyoPax an innovative European biotech startup focused on developing regenerative cell therapies for debilitating muscle disorders has achieved a significant milestone in its efforts to help children with rare diseases
European Medicines Agency Grants Orphan Drug Designation to Marker Therapeutics' MT-401 for AML Treatment
Tuesday, July 11, 2023Marker Therapeutics Inc Nasdaq MRKR has recently announced that its T cellbased immunotherapy zedenoleucel MT has been granted Orphan Drug Designation by the European Medicines Agency EMA for the treatment of acute myeloid leukemia AML
